Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Healthcare-associated parechovirus-A infection in hospitals with neonatal units in Japan: a nationwide survey.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

BCOR-CCNB3 fusion-positive sarcoma treated with chemotherapy and carbon-ion radiotherapy: a case report of long-term disease control of a cervical spine case with a 12-year follow-up.

Frontiers in oncology·2026
Same author

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity.

Frontiers in oncology·2026
Same author

NKG2D-based CAR-T cells for synovial sarcoma: A preclinical proof-of-concept study.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Prospective use of wastewater surveillance for early detection of enterovirus D68 in community outbreaks among children, Niigata City, Japan, 2024.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Disappearance of histone H3F3A mutation in metastatic giant cell tumor of bone during long term follow up.

Discover oncology·2026

相关实验视频

Updated: Sep 9, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K

通过使用多种细胞因子和抗CD2和抗NKp46刺激抗体,产生仿真抗原受体转化原始人类杀手细胞的新方法

Nobuhiro Kubo1, Minori Baba1, Chansu Shin1

  • 1Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|August 29, 2025
PubMed
概括

研究人员开发了一种新的方法来产生异性化基因抗原受体 (CAR) -自然杀手 (NK) 细胞的临床剂量. 这种方法提高了CAR-NK细胞扩张和转导效率,从而改善了癌症免疫疗法.

关键词:
卡尔-NK细胞癌症免疫疗法化学抗原受体 (CAR)活体扩张自然杀手 (NK) 细胞

更多相关视频

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

5.8K
Generation of Natural Killer Cells from Human Expanded Potential Stem Cells
06:53

Generation of Natural Killer Cells from Human Expanded Potential Stem Cells

Published on: January 13, 2023

3.2K

相关实验视频

Last Updated: Sep 9, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.0K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

5.8K
Generation of Natural Killer Cells from Human Expanded Potential Stem Cells
06:53

Generation of Natural Killer Cells from Human Expanded Potential Stem Cells

Published on: January 13, 2023

3.2K

科学领域:

  • 免疫学
  • 细胞生物学
  • 生物技术

背景情况:

  • 异构基因抗原受体 (CAR) -天然杀手细胞 (NK) 显示出治疗血液恶性瘤的前景.
  • 目前生产CAR-NK细胞的方法涉及费用昂贵且难以扩展的料细胞.
  • 现有方法存在污染和可扩展性问题的风险.

研究的目的:

  • 开发一种改进的NK细胞临床剂量生成系统.
  • 增强原始人类NK细胞的体外扩张和基因修饰.
  • 创建一个更有效和可扩展的CAR-NK细胞生产方法.

主要方法:

  • 使用细胞因子 (IL-2,IL-12,IL-18,IL-21) 和向CD2和NKp46的抗体进行了原始人体NK细胞扩增.
  • 使用逆转录病毒载体用抗CD19-BB-ζCAR转化激活的NK细胞.
  • 评估了CAR-NK细胞对B细胞瘤的疗效.

主要成果:

  • 一个新的培养系统成功地扩展和激活了人类的NK细胞.
  • 使用CAR实现了NK细胞的高效转导.
  • 抗CD19-CAR-NK细胞对B细胞瘤具有强烈的细胞毒性.

结论:

  • 开发的系统有效地扩展和基因修饰初级NK细胞.
  • 这种方法为CAR-NK细胞生产提供了可扩展和潜在的安全替代方案.
  • 这一进步有助于开发基于CAR-NK细胞的异性癌症免疫疗法.